Allarity Therapeutics, Inc.
ALLRAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | Sep 16, 2026 |
| Ascendiant Capital | maintain | Buy | Jun 8, 2026 |
| Ascendiant Capital | maintain | Buy | Apr 10, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 9, 2025 |
| Ascendiant Capital | maintain | Buy | Sep 26, 2025 |
| Ladenburg Thalmann | downgrade | Buy →Neutral | Aug 23, 2022 |
| Ladenburg Thalmann | maintain | Buy | May 27, 2022 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.21| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.21 | $-0.25 | — | — |
| May 15, 2026 | $-0.17 | $-0.22 | $25.0K | $25.0K |
| Mar 31, 2026 | $-0.19 | $-0.22 | $320.0K | $320.0K |
| Nov 14, 2025 | $-0.19 | $-0.23 | — | — |
| Aug 15, 2025 | $-0.15 | $-0.21 | — | — |
| May 9, 2025 | $-0.25 | — | — | — |
| Apr 4, 2025 | $-4.73 | $-8.10 | $6.0K | — |
| Nov 14, 2024 | $-7.71 | $-8.52 | — | — |
News
- Agreement complements revenue from standard gene expression and DRP® services - Development and validation services will support a European biotechnology company's precision oncology predictive device for use in the United States - Strategy expands commercial use of existing laboratory capabilities - Stenoparib remains the Company's top development priority TARPON SPRINGS, Fla., October 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stag…
After losing some value lately, a hammer chart pattern has been formed for Allarity Therapeutics, Inc. (ALLR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Evogene (NASDAQ: EVGN - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership. Institutional and Insider Ownership 10.4% of Evogene shares
Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) and Autolus Therapeutics (NASDAQ: AUTL - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings. Analyst Recommendations This is a breakdown of
- Recently awarded patents have solidified Allarity's strategy to leverage DRP to ensure the commercial exclusivity of stenoparib TARPON SPRINGS, Fla., September 30, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor— today provided an update on recent advances in its proprietary Drug Response Predictor (DRP®) technology, …
- Expanded laboratory capabilities support deeper mechanism-of-action research for stenoparib - New proteomics and cell line capabilities will broaden Allarity's research capabilities to enable external partnerships
Xenetic Biosciences (NASDAQ: XBIO - Get Free Report) and Allarity Therapeutics (NASDAQ: ALLR - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends. Analyst Recommendations This is a breakdown of
TARPON SPRINGS, Fla., September 15, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced that the Japan Patent Office (JPO) has granted a key patent covering Allarity's proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic.
TARPON SPRINGS, Fla., September 11, 2026 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor using its proprietary DRP® technology, announced that Allarity Acquisition Corp., a newly formed special purpose acquisition company (SPAC), has publicly filed a Registration Statement on Form S-1 (the “Registration Statement”) with the U.S. Securitie…
- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP ® companion diagnostic into 2042 - AACR 2026 data linked higher stenoparib DRP ® scores with enhanced overall survival in advanced ovarian cancer, further supporting DRP ® -guided patient selection - Obtained CLIA certification for its in-house laboratory, enabling full control of DRP ® testing to accelerate and support …